

Form 45-106F6***British Columbia Report of Exempt Distribution***

This is the form required under section 6.1 of National Instrument 45-106 for a report of exempt distribution in British Columbia.

Issuer/underwriter information**Item 1: Issuer/underwriter name and contact information**

Network Oncology Inc.
500-900 Hastings Street West
Vancouver BC V6C 1E5
Tel: 604-617-7221
Email : dagcorp123@gmail.com

Item 2: Reporting issuer status

The issuer is a reporting issuer in BC and Alberta and as of the date of this report it is also reporting in Ontario.

Item 3: Issuer's industry

Indicate the industry of the issuer by checking the appropriate box below.

- | | |
|---|--|
| <input checked="" type="checkbox"/> Bio-tech | Mining |
| Financial Services | <input type="checkbox"/> exploration/development |
| <input type="checkbox"/> investment companies and funds | <input type="checkbox"/> production |
| <input type="checkbox"/> mortgage investment companies | <input type="checkbox"/> Oil and gas |
| <input type="checkbox"/> Forestry | <input type="checkbox"/> Real estate |
| <input type="checkbox"/> Hi-tech | <input type="checkbox"/> Utilities |
| <input type="checkbox"/> Industrial | <input type="checkbox"/> Other (describe) |

Item 4: Insiders and promoters of non-reporting issuers

If the issuer is an investment fund managed by an investment fund manager registered in a jurisdiction of Canada, do not complete this table.

If the issuer is not a reporting issuer in any jurisdiction of Canada, complete the following table by providing information about each insider and promoter of the issuer. If the insider or promoter is not an individual, complete the table for directors and officers of the insider or promoter.

Information about insiders and promoters			
Full name, municipality and country of principal residence	All positions held (e.g., director, officer, promoter and/or holder of more than 10% of voting securities)	Number and type of securities of the issuer beneficially owned or, directly or indirectly controlled, on the distribution date, including any securities purchased under the distribution	Total price paid for all securities beneficially owned or, directly or indirectly controlled, on the distribution date, including any securities purchased under the distribution (Canadian \$)
NA			

Details of distribution**Item 5: Distribution date**

January 12, 2015

Item 6: Number and type of securities

- 12,500,000 Units - Each Unit was issued at a price of \$0.02 per Unit. Each Unit is comprised of one common share and one share purchase warrant to purchase an additional share at \$0.05 per warrant shares for a 12 month term from the date of issue.
- 17,000,000 common shares issued at a deemed price of \$0.02 per share per an Asset Acquisition.

The Issuer relied on the exemptions provided by National Instrument 45-106 (“NI 45-106”) section 2.3 (accredited investor) for \$250,000; and section 2.12 (asset acquisition) for \$340,000.

Item 7: Geographical information about purchasers

Each Canadian and foreign jurisdiction where purchasers reside	Number of purchasers	Price per security (Canadian \$) ¹	Total dollar value raised from purchasers in the jurisdiction (Canadian \$)
British Columbia	1	\$ 0.02	\$ 25,000
British Columbia	1	\$ 0.02 ⁽¹⁾	\$ 10,000
USA	1	\$ 0.02 ⁽¹⁾	\$ 20,000
Hong Kong	2	\$ 0.02	\$ 110,000
Cyprus	1	\$ 0.02	\$ 55,000
Belize	1	\$ 0.02	\$ 60,000
Ireland	2	\$ 0.02 ⁽¹⁾	\$ 220,000
Panama	1	\$ 0.02 ⁽¹⁾	\$ 90,000
Total number of Purchasers	10		
Total dollar value of distribution in all jurisdictions (Canadian \$)			\$590,000.00

⁽¹⁾ Deemed value for asset acquisition

Item 8: Information about purchasers

Information about non-individual purchasers					
Full name and address of purchaser and name and telephone number of a contact person	Indicate if the purchaser is an insider (I) of the issuer or a registrant (R)	Number and type of securities purchased	Total purchase price (Canadian \$)	Exemption relied on	Date of distribution (yyyy-mm-dd)
Utovez Consulting Ltd 17C Thomson Comm Building, 8 Thomson Road, Wanchai, Hong Kong David Perez Tel: +85258086072		2,367,000 Shares 2,367,000 Warrants	\$47,340	s. 2.3 of NI 45-106	2015-01-12
Vestamint Enterprises Ltd. Room 1202, Alliance Building, 130 - 136 Connaught Road, Central, Hong Kong Bradon Gillett Tel: +85258086013		3,133,000 Shares 3,133,000 Warrants	\$62,660	s. 2.3 of NI 45-106	2015-01-12
Arancio Investments Ltd. Armenias 23, Alastor Block A, Office 103, 2003 Nicosia, Cyprus Roger Knox Tel: +41 79 198 93 56		2,750,000 Shares 2,750,000 Warrants	\$55,000	s. 2.3 of NI 45-106	2015-01-12
Brabant Limited 76 Dean Street, Belize City, Belize S. Burt Tel: +41 22575 39 11		3,000,000 Shares 3,000,000 Warrants	\$60,000	s. 2.3 of NI 45-106	2015-01-12
Resolute Oncology, Ltd. 27 Cork Road, Midleton, County Cork, Ireland Sean Maenpaa Tel: +353 (0)87 4601340		10,000,000 Shares	\$200,000 (asset)	s. 2.12 of NI 45-106	2015-01-12

Polaris Global S.A. 53rd Street, Urbanizacion Marbella, MMG Tower, Panama City, Panama Jacqueline Binggeli Tel: +41 44 287 10 90		4,500,000 Shares	\$90,000 (asset)	s. 2.12 of NI 45-106	2015-01-12
		25,750,000	\$515,000.00		

Commissions and finder's fees

Item 9: Commissions and finder's fees

Full name and address of the person being compensated	Indicate if the person being compensated is an insider (I) of the issuer or a registrant (R)	Compensation paid or to be paid (cash and/or securities)				
		Cash (Canadian \$)	Securities			Total dollar value of compensation (Canadian \$)
			Number and type of securities issued Warrants same terms as Above	Price per security (Canadian \$)	Exemption relied on and date of distribution (yyyy-mm-dd)	
N/A						

Certificate

On behalf of the Network Oncology Inc., I certify that the statements made in this report are true.

Date: January 22, 2015

Network Oncology Inc.

/s/ Sean Maenpaa – President/CEO

Signature

Item 10: Contact information

Monita Faris – 778-370-1372

Monita.faris@gmail.com

IT IS AN OFFENCE TO MAKE A MISREPRESENTATION IN THIS REPORT.